Last edition
News about Global Pharma
Novo Nordisk Appoints Maziar Mike Doustdar as New CEO, Announces Key Organisational Changes
Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen, who will step down as President and Chief Executive Officer of Novo Nordisk next month.
Global Pharma | 30/07/2025 | By Dineshwori | 597
Johnson and Johnson Unveils AI Solution for Bunion Surgery, Seeks FDA Nod to Expand TREMFYA Label
Johnson and Johnson MedTech has announced the launch of the VIRTUGUIDE System, an advanced AI-powered solution designed to support Lapidus procedures—a common type of bunion surgery.
Global Pharma | 30/07/2025 | By Dineshwori | 172
Novo Nordisk Cuts Annual Outlook Again as Wegovy Supply Woes Persist
Shares of Novo Nordisk fell sharply after the company once again lowered its annual forecast, citing ongoing supply challenges for its blockbuster obesity drug Wegovy. Despite a 25% jump in second-quarter sales and a 28% rise in net profit, the Danish drugmaker scaled back expectations for full-year operating profit and sales growth.
Global Pharma | 30/07/2025 | By Darshana | 128
Novartis India Appoints DC Dave and Co as Cost Auditors for FY 2025-26
Novartis India has appointed M/s. DC Dave and Co., a firm of practicing cost accountants, as the cost auditors of the company for the financial year 2025–26.
Global Pharma | 29/07/2025 | By Dineshwori | 146
Veranova Names Thomas Rohrer as Vice President of Bioconjugation
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation.
Global Pharma | 29/07/2025 | By Dineshwori | 253
Dr. Reddy's Injects INR 565 Crore into Russian Arm
Dr Reddy’s Laboratories Ltd has invested INR 565.4 crore in its Russian arm, Dr Reddy’s Laboratories LLC (DRL Russia), acquiring a 45.19 percent equity stake in the step-down wholly-owned subsidiary.
Global Pharma | 29/07/2025 | By Dineshwori | 649
PTC Therapeutics Secures US FDA Approval for SEPHIENCE
PTC Therapeutics has received FDA approval for SEPHIENCE (sepiapterin) to treat sepiapterin-responsive phenylketonuria (PKU) in patients aged one month and older, offering a new therapy for managing this rare metabolic disorder.
Global Pharma | 29/07/2025 | By Mrinmoy Dey | 334
Kinvard Bio has secured USD 2.7 million in follow-on non-dilutive funding from CARB-X to advance its novel ribosome-targeting antibiotics toward preclinical development, tackling drug-resistant infections like MRSA and cUTI.
Global Pharma | 29/07/2025 | By Mrinmoy Dey | 177
AstraZeneca Reports 11 Percent Revenue Growth, Commits to USD 50 Bn US Expansion
For H1 2025, AstraZeneca’s total revenue rose 11 percent at constant exchange rates (CER) to USD 28.0 billion, driven by double-digit growth in both its oncology and biopharmaceuticals divisions.
Global Pharma | 29/07/2025 | By Dineshwori | 319
Merck, BMS, Pfizer to Be Hit Hard by Looming Patent Cliff: Report Warns
Major pharmaceutical players, including Merck, Bristol Myers Squibb (BMS), Johnson and Johnson, Pfizer, and Novartis, are expected to experience significant revenue losses as several of their blockbuster drugs approach patent expirations, according to a new report by Research and Markets.
Global Pharma | 28/07/2025 | By Dineshwori | 756
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy